HDAC9 and idiopathic pulmonary fibrosis: In summary, all these studies prove the significant antifibrotic efficacy of Class I-selective HDAC inhibitors in preclinical models of lung fibrosis and underscore the crucial role of Class I HDACs in mediating profibrotic signalling in IPF/fibrotic lung fibroblasts.